Share This Page
Suppliers and packagers for seromycin
✉ Email this page to a colleague
seromycin
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Sanaluz | SEROMYCIN | cycloserine | CAPSULE;ORAL | 060593 | ANDA | Dr. Reddy?s Laboratories, Inc. | 43598-235-31 | 3 BLISTER PACK in 1 CARTON (43598-235-31) / 10 CAPSULE in 1 BLISTER PACK (43598-235-10) | 2023-03-15 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Seromycin
Introduction
Seromycin, known generically as isoniazid, is a critical antibiotic primarily used in the treatment of tuberculosis (TB). Its role as a cornerstone in multidrug therapy for TB underscores the importance of reliable suppliers for this medication. Given the global health implications and the complex manufacturing process involved, understanding the landscape of Seromycin suppliers is vital for healthcare providers, government agencies, and pharmaceutical companies seeking to ensure supply chain stability.
Overview of Seromycin and Its Medical Importance
Seromycin's active compound, isoniazid, was discovered in the 1950s and remains a first-line agent against Mycobacterium tuberculosis. Its widespread use in TB regimens underscores its significance, especially in achieving treatment success and preventing drug resistance. As TB continues to be a major health concern worldwide, especially in low- and middle-income countries, the demand for high-quality Seromycin persists.
Global Manufacturing Landscape
The production of Seromycin involves sophisticated chemical synthesis and stringent quality control protocols to meet international pharmaceutical standards, such as Good Manufacturing Practices (GMP). The complexity of synthesis—primarily through chemical processes—limits the pool of qualified manufacturers to those with advanced pharmaceutical manufacturing capabilities.
Leading Suppliers of Isoniazid (Seromycin)
1. GSK (GlaxoSmithKline)
GSK historically played a pivotal role in supplying Isoniazid globally. Although GSK has transitioned from direct manufacturing to licensing certain pharmaceutical products, their contribution to the development and standardization of Seromycin is notable. Certain formulations are still available in select markets through licensing agreements with generic manufacturers.
2. Sanofi
Sanofi is recognized for producing high-quality anti-tuberculosis drugs, including Isoniazid. The company supplies both branded and generic formulations to governments and international health agencies, especially in Africa and Asia, under programmatic procurement efforts.
3. Lupin Limited
An Indian pharmaceutical giant, Lupin has developed a significant portfolio of anti-TB medicines, including Isoniazid. Their extensive manufacturing capacity and compliance with global quality standards position them as a reliable supplier for both domestic and international markets.
4. Mylan (Now part of Viatris)
Mylan has manufactured generic Isoniazid, accommodating the high-volume needs of TB treatment programs worldwide. Their global distribution channels make them a key supplier for NGOs and government agencies.
5. Cipla
Cipla—a South African-based multinational—produces a broad range of generic anti-TB medications, including high-quality Isoniazid formulations. Their focus on affordability and availability in resource-limited settings aligns with global health needs.
6. Zhejiang Jinhua Tongxin Pharmaceutical Co., Ltd.
A Chinese supplier that produces pharmaceutical-grade Isoniazid, primarily serving the domestic market but increasingly expanding to export markets.
7. Hetero Labs Limited
An Indian manufacturer specializing in generic medicines, Hetero produces Isoniazid capsules and tablets for various markets, especially in developing countries.
Emerging and Regional Suppliers
Beyond these established players, several regional manufacturers in India, China, and Eastern Europe have ramped up production to meet growing demand in endemic regions. Many of these companies seek WHO Prequalification or European Medicines Agency (EMA) approval to expand their export reach.
Regulatory Status and Quality Assurance
Supply reliability hinges on regulatory approvals, quality standards, and compliance with international guidelines. WHO prequalification plays a critical role in enabling procurement by global health agencies, including the Global Drug Facility (GDF). Many top suppliers have achieved this status, ensuring their products meet safety, efficacy, and quality benchmarks.
Challenges in the Seromycin Supply Chain
Despite a relatively established manufacturing landscape, supply vulnerabilities persist due to:
- Raw Material Shortages: Limited availability of high-purity chemicals used in synthesis can delay production.
- Regulatory Delays: Variations in approval timelines hinder market entry for newer manufacturers.
- Manufacturing Capacity Constraints: Sudden spikes in demand, especially during health emergencies, strain existing production capacities.
- Intellectual Property and Licensing: Patents and licensing agreements influence market access, especially in low-income regions.
Future Outlook
The continued global emphasis on TB elimination and antimicrobial resistance necessitates diversifying and strengthening the supply chain for Seromycin. Investment in manufacturing capacity, alternative synthesis methods, and regional production hubs will be crucial. Pandemic responses, such as COVID-19, underscored the importance of resilient pharmaceutical supply chains, providing lessons that apply to essential medicines like Isoniazid.
Conclusion
Reliable suppliers of Seromycin, primarily through the production of Isoniazid, form the backbone of global TB control efforts. Leading companies—including GSK, Sanofi, Lupin, Mylan/Viatris, and Cipla—dominate the market, with regional manufacturers making notable contributions. Ensuring consistent quality, regulatory compliance, and supply chain resilience remains key to meeting worldwide treatment needs.
Key Takeaways
- Dominant Suppliers: Major pharmaceutical firms such as GSK, Sanofi, Lupin, Mylan/Viatris, and Cipla lead the supply of Isoniazid (Seromycin).
- Global Procurement: WHO prequalification and regulatory approvals are critical for suppliers aiming at international markets and TB programs.
- Supply Chain Challenges: Raw material shortages, capacity constraints, and regulatory delays threaten supply stability.
- Emerging Markets: Regional manufacturers in China, India, and Eastern Europe are expanding their role, increasing market diversity.
- Future Strategies: Investment in manufacturing capacity and regional production, along with regulatory harmonization, will bolster supply resilience.
FAQs
1. Who are the leading global suppliers of Seromycin?
Major suppliers include GSK (historically), Sanofi, Lupin, Mylan (Viatris), and Cipla, all producing pharmaceutical-grade Isoniazid essential for TB treatment.
2. What certifications should suppliers have to qualify for international procurement?
Suppliers should secure WHO prequalification, EMA approval, or national regulatory agency approval to ensure quality and facilitate procurement by global health agencies.
3. How do supply chain disruptions impact TB treatment programs?
Disruptions can lead to drug shortages, treatment interruptions, and increased risk of drug resistance, undermining global TB control efforts.
4. Are there regional manufacturers producing Seromycin?
Yes, companies in China, India, and Eastern Europe manufacture Isoniazid, contributing to diversified supply sources, especially for resource-limited settings.
5. What is the outlook for future Seromycin supply stability?
Enhanced manufacturing capacity, regional production, and regulatory harmonization will improve supply stability, vital for ongoing TB eradication initiatives.
Sources
[1] WHO. (2021). Global tuberculosis report.
[2] IMS Health. (2022). Global Pharmaceutical Market Data.
[3] Global Drug Facility. (2022). Procurement Guidelines for Anti-TB Drugs.
[4] Pharmaceutical Business Reports. (2023). Anti-Tuberculosis Drug Market Analysis.
[5] Company Websites: Sanofi, Lupin, Mylan, Cipla, Zhejiang Jinhua Tongxin Pharmaceutical.
More… ↓
